Xanodyne Pharmaceuticals, Inc. has received an approvable letter from the U.S. Food and Drug Administration (FDA) for Zipsor, its candidate for the treatment of patients with mild to moderate acute pain. Gregory Flexter, president and CEO of the Newport-based company, said Xanodyne has been informed that no additional clinical trials have been requested and said the company will work closely with the FDA to provide a complete response.
-
Share This!
Newport
August 1, 2008
360 Views
You may also like
Popular Stories
The Lane Report
- Give 270 to raffle rare $15,000 Kentucky Derby 150: Baccarat Edition whiskey
- Julie Thomas has been appointed account executive of United Direct Solutions
- 37 are members of Leadership Lake Cumberland Class of 2024
- Land trust River Fields names first new president in 38 years
- Glick Opens Government Affairs/Political Consulting Firm
- UofL Health to build $25M Center for Rural Cancer Education and Research
- Cancer patients, caregivers benefit from services to guide legal, financial issues
- Burkesville utility building maker on Financial Times’ fastest growing list
- Aid helping Kentuckians reinvent mountain economy; much more on the way
- National magazine gives Impact Award for Toyota’s $1.3B Ky investment
Add Comment